TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20870109

Group type: EXPERIMENTAL
Intervention: 1‐piece acrylic foldable IOL (AcrySof SA60AT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 3‐piece acrylic foldable IOL (AcrySof MA60AC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Both IOL groups
Number of subjects: 125
Study: 18394567

Group type: EXPERIMENTAL
Intervention: Spheramine (stereotactic implantation into the striatum)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Spheramine (bilateral implantation into the postcommissural putamen)
Number of subjects: 6
Study: 15943672

Group type: EXPERIMENTAL
Intervention: Verbal paired‐associate and verbal learning tests of various lengths
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Verbal paired‐associate and verbal learning tests
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Optimal test lengths for verbal paired‐associate and verbal list‐learning tests
Number of subjects: 208
Study: 12581490

Group type: EXPERIMENTAL
Intervention: Rebif (IFN-beta1a) at 44 microg t.i.w.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betaseron (IFN-beta1b)
Number of subjects: 0
Study: 10355071

Group type: COMPARATOR
Intervention: Intravenous enalaprilat (initial dose: 2.5 mg; repetitive application of 2.5 mg every 30 min until a cumulative dose of 10 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (initial dose: 0.8 mg; repetitive application of 0.8 mg every 10 min until a cumulative dose of 3.2 mg)
Number of subjects: 46
Study: 8574735

Group type: COMPARATOR
Intervention: omeprazole
Number of subjects: 65

Group type: COMPARATOR
Intervention: lansoprazole
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: lansoprazole+plaunotol
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: lansoprazole+clarithromycin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: lansoprazole+plaunotol+clarithromycin
Number of subjects: 65
Study: 1790550

Group type: EXPERIMENTAL
Intervention: 50 mg of oral ubidecarenone daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ubidecarenone)
Number of subjects: 20
Study: 7214795

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluocortinbutyl (FCB) 40 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29847252

Group type: EXPERIMENTAL
Intervention: Total cost information displayed (66.2% acceptance)
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Total cost information displayed for another person (68.0% acceptance)
Number of subjects: 1211

Group type: COMPARATOR
Intervention: No total cost information displayed (58.0% acceptance)
Number of subjects: 1211

Group type: COMPARATOR
Intervention: No total cost information displayed for another person (56.4% acceptance)
Number of subjects: 1211
Study: 29489106

Group type: EXPERIMENTAL
Intervention: Local anesthesia with continuous anesthetic
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthesia with bolus anesthetic
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bilateral blockade of the cross-space belly
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multimodal analgesia system
Number of subjects: 120
Study: 23630403

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 382

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 382
Study: 23941761

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LaCO3)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19861658

Group type: EXPERIMENTAL
Intervention: History of PAD
Number of subjects: 299

Group type: COMPARATOR
Intervention: No history of PAD
Number of subjects: 299
Study: 18250184

Group type: EXPERIMENTAL
Intervention: REClari (Clarithromycin)
Number of subjects: 371

Group type: COMPARATOR
Intervention: RECipro (Ciprofloxacin)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: M vaccae immunotherapy
Number of subjects: 371
Study: 16427745

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time‐matched comparison condition (health education and scheduled, reduced smoking)
Number of subjects: 0
Study: 12824212

Group type: EXPERIMENTAL
Intervention: Undiluted smallpox vaccine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diluted smallpox vaccine (1:3.2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diluted smallpox vaccine (1:10)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diluted smallpox vaccine (1:32)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vaccinia‐naive participants (undiluted vaccine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non‐naive participants
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vaccinia‐naive participants
Number of subjects: 90
Study: 12212115

Group type: EXPERIMENTAL
Intervention: BZX (bizhongxiao decoction)
Number of subjects: 96

Group type: COMPARATOR
Intervention: MTX (methotrexate)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: BZX
Number of subjects: 96

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 96
Study: 8814042

Group type: EXPERIMENTAL
Intervention: Benzyl benzoate application to mattresses and carpets in addition to usual mite control measures.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual house dust mite control measures including vinyl covers for mattresses and pillows.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Benzyl benzoate application to mattresses and carpets.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual house dust mite control measures.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Benzyl benzoate application and usual control measures.
Number of subjects: 26
Study: 1582788

Group type: EXPERIMENTAL
Intervention: Topical carteolol 1%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 4015065

Group type: EXPERIMENTAL
Intervention: apalcillin 75 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: apalcillin 150 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: apalcillin 225 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: apalcillin (all doses)
Number of subjects: 21
Study: 31727915

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 30073307

Group type: EXPERIMENTAL
Intervention: e-book readings supplemented with vocabulary instruction (scaffolding through explanations in Spanish, repetition in English, checks for understanding, and highlighted morphology)
Number of subjects: 288

Group type: COMPARATOR
Intervention: read-only condition (control group)
Number of subjects: 288
Study: 26825021

Group type: EXPERIMENTAL
Intervention: 20-30 mg/24h morphine SR
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 1441866

Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.125% with 12.5 micrograms epinephrine (test dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 ml normal physiologic saline (control)
Number of subjects: 40
Study: 23134737

Group type: EXPERIMENTAL
Intervention: Muscle Strength Training (ST)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Muscle Power Training (PT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 69
Study: 21080835

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1653
Study: 18459121

Group type: EXPERIMENTAL
Intervention: Meditation with yoga (and psychoeducation)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Group therapy with hypnosis (and psychoeducation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Psychoeducation alone
Number of subjects: 46
Study: 16392991

Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Group Care (GC)
Number of subjects: 81
Study: 12507634

Group type: EXPERIMENTAL
Intervention: Lutein (15 mg, n = 5)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Alpha-tocopherol (100 mg, n = 6)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 17
Study: 10570588

Group type: EXPERIMENTAL
Intervention: OralCDx analysis
Number of subjects: 945

Group type: COMPARATOR
Intervention: Scalpel biopsy
Number of subjects: 945
Study: 8888117

Group type: EXPERIMENTAL
Intervention: Niacin supplementation
Number of subjects: 0
Study: 1497931

Group type: EXPERIMENTAL
Intervention: Lidoflazine 1 mg/kg intravenously over a period of 20 min before initiation of cardiopulmonary bypass
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 93
Study: 3914085

Group type: EXPERIMENTAL
Intervention: Intermittent traction
Number of subjects: 100

Group type: COMPARATOR
Intervention: No traction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Static traction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 100
Study: 30596265

Group type: EXPERIMENTAL
Intervention: Expert moderated vaccine social media (VSM) website
Number of subjects: 367

Group type: COMPARATOR
Intervention: Publicly available parenting and vaccine-focused blogs and discussion forums
Number of subjects: 367
Study: 30381628

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 14564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14564
Study: 25952586

Group type: EXPERIMENTAL
Intervention: Video-games group (N=24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional therapy group (N=23)
Number of subjects: 47
Study: 24841348

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node dissection (SLND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual tracer technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 0
Study: 20438194

Group type: EXPERIMENTAL
Intervention: RELATE + Couple CARE
Number of subjects: 59

Group type: COMPARATOR
Intervention: RELATE
Number of subjects: 59
Study: 16370155

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 63
Study: 11952579

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment (0.2%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diltiazem hydrochloride (DTZ) cream (2%)
Number of subjects: 60
Study: 9458470

Group type: EXPERIMENTAL
Intervention: SPf66 (0.5 mg or 1.0 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SPf66 (high dose Colombian vaccine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SPf66
Number of subjects: 150

Group type: COMPARATOR
Intervention: Inactivated polio vaccine
Number of subjects: 150
Study: 7872410

Group type: EXPERIMENTAL
Intervention: Unilateral and bilateral tachistoscopic stimulation (the Dimond paradigm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poffenberger paradigm with varying memory load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poffenberger paradigm with field/hand/load interaction
Number of subjects: 0
Study: 3127188

Group type: EXPERIMENTAL
Intervention: Phenytoin sodium capsules 400 mg with enteral feedings (Ensure) at 100 ml/h for ten hours
Number of subjects: 6

Group type: COMPARATOR
Intervention: Phenytoin sodium capsules 400 mg without enteral feedings
Number of subjects: 6
Study: 11564991

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg o.d. (or valsartan 80 mg + HCTZ 12.5 mg o.d. after 4 weeks if needed)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Amlodipine 5 mg o.d. (or amlodipine 10 mg o.d. after 4 weeks if needed)
Number of subjects: 690
Study: 30720640

Group type: EXPERIMENTAL
Intervention: Water-based aerobic interval training (24 sessions)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 29474934

Group type: EXPERIMENTAL
Intervention: 1-dose regimen of HPV vaccine
Number of subjects: 24000

Group type: COMPARATOR
Intervention: 2-dose regimen of HPV vaccine
Number of subjects: 24000

Group type: COMPARATOR
Intervention: Unvaccinated girls (observational study)
Number of subjects: 24000
Study: 26955763

Group type: EXPERIMENTAL
Intervention: Primary Care Pathway for Childhood Asthma intervention, which includes an electronic guide and train-the-trainer education for chronic disease management health professionals.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but implied to be standard care without the intervention.
Number of subjects: 0
Study: 24641624

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (8 g day(-1) containing 1.6 g day(-1) eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High oleic sunflower oil (8 g day(-1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 36
Study: 22717030

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 20802297

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Darunavir/ritonavir triple drug regimen
Number of subjects: 225
Study: 16782174

Group type: EXPERIMENTAL
Intervention: IL6 polymorphisms (specifically the -572 G>C polymorphism)
Number of subjects: 3027

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3027
Study: 15157691

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 3-4 weeks at anti-pain acupoints)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment (10 sessions over 3-4 weeks at placebo-points)
Number of subjects: 24
Study: 11233459

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 59
Study: 9442782

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) administered once daily for 6 months
Number of subjects: 277

Group type: COMPARATOR
Intervention: Timolol (0.5%) administered twice daily for 6 months
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) administered once daily for 18 months
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) administered once daily for 24 months
Number of subjects: 277
Study: 7992902

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fentanyl 4.5 micrograms/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Esmolol 0.75 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine 4.3 micrograms/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Desflurane (control)
Number of subjects: 10
Study: 2729906

Group type: EXPERIMENTAL
Intervention: Pipram (pipemidic acid) 200 mg daily at bedtime for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pipram (pipemidic acid)
Number of subjects: 70
Study: 5100498

Group type: EXPERIMENTAL
Intervention: Gradual introduction of treatment with levodopa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rapid introduction of treatment with levodopa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elderly patients (aged 65 and over)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Younger patients (under 65)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rate of increasing the dose of levodopa
Number of subjects: 20
Study: 31573644

Group type: EXPERIMENTAL
Intervention: Redesigned simulation and redistribution of clinical hours in intervention group
Number of subjects: 586

Group type: COMPARATOR
Intervention: Traditional clinical instruction in control group
Number of subjects: 586
Study: 28217868

Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Scopolamine 0.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25872301

Group type: EXPERIMENTAL
Intervention: Implant anchorage
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Extraoral anchorage
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nance arch anchorage
Number of subjects: 46
Study: 24649784

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETT)
Number of subjects: 90
Study: 21496949

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (800 mg by mouth three times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18779378

Group type: EXPERIMENTAL
Intervention: Cinaciguat (50-250 microg/h) administered intravenously for up to 4 hours
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cinaciguat (150-250 microg/h) administered intravenously for up to 4 hours
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16813911

Group type: EXPERIMENTAL
Intervention: 10 nM resiniferatoxin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vehicle (10% ethanol in normal saline)
Number of subjects: 54
Study: 15220787

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural fentanyl and lidocaine before incision (group 1)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural fentanyl and lidocaine after incision (group 2)
Number of subjects: 141

Group type: COMPARATOR
Intervention: General anesthesia plus a sham epidural (group 3)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 141
Study: 11099083

Group type: EXPERIMENTAL
Intervention: 1-day intramuscular ceftriaxone (50 mg/kg)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 3-day intramuscular ceftriaxone (50 mg/kg/day)
Number of subjects: 109
Study: 9495995

Group type: EXPERIMENTAL
Intervention: Psychological suggestion therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spontaneous birth processes (Control)
Number of subjects: 120
Study: 8394842

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Seleparina, CY 216) administered as 2 x 3,825 anti‐Xa international units subcutaneously on the day of surgery followed by a single daily 3,825 anti‐Xa international units injection for 7 days.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no prophylaxis).
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Seleparina, CY 216).
Number of subjects: 61
Study: 2941473

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (active medication)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study: 29754651

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 830
Study: 26880010

Group type: EXPERIMENTAL
Intervention: Conventional NAM treatment (Group 1, n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CAD/CAM NAM (Group 2, n = 6)
Number of subjects: 12
Study: 24129264

Group type: EXPERIMENTAL
Intervention: School-based smoking intervention program lasting one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22301075

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (in patients with Giardia lamblia)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (in patients with no identified enteropathogen)
Number of subjects: 100
Study: 20483885

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18395902

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis Bb12 (Bb12)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Propionibacterium freudenreichii ssp. shermanii JS (PJS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 15814016

Group type: EXPERIMENTAL
Intervention: Biannual guaiac-based FOB test with three test cards for consecutive samples
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control group (non-invited individuals)
Number of subjects: 20000
Study: 12417389

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 170
Study: 10065817

Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Not performing Omentoplasty (NO)
Number of subjects: 115
Study: 7554206

Group type: EXPERIMENTAL
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 171

Group type: COMPARATOR
Intervention: Circulatory arrest
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Low-flow cardiopulmonary bypass and Circulatory arrest
Number of subjects: 171
Study: 2404841

Group type: EXPERIMENTAL
Intervention: Doxorubicin (20 mg/m2 day 1 and 8) in combination with PCOP regimen (cyclophosphamide 400 mg/m2 day 1 and 8, vincristine 1.4 mg/m2 day 1 and 8, procarbazine 80 mg/m2 day 1 to 14, prednisone 60 mg/m2 day 1 to 5)
Number of subjects: 113

Group type: COMPARATOR
Intervention: PCOP regimen without doxorubicin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Doxorubicin (20 mg/m2 day 1 and 8)
Number of subjects: 113
Study: 6776543

Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg or occasionally 4 mg/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 31488360

Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide (100 mg/m2 on day 1 plus 100-200 mg/m2 on days 2-6 for six 6-week courses)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Temozolomide (75 mg/m2 daily during radiotherapy plus six 4-week courses of temozolomide [150-200 mg/m2] on days 1-5)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide
Number of subjects: 141
Study: 28160217

Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 mg
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340